CN101879155B - Method for preparing dan hong for injection - Google Patents
Method for preparing dan hong for injection Download PDFInfo
- Publication number
- CN101879155B CN101879155B CN2010102365632A CN201010236563A CN101879155B CN 101879155 B CN101879155 B CN 101879155B CN 2010102365632 A CN2010102365632 A CN 2010102365632A CN 201010236563 A CN201010236563 A CN 201010236563A CN 101879155 B CN101879155 B CN 101879155B
- Authority
- CN
- China
- Prior art keywords
- danhong
- injection
- specific embodiment
- flos carthami
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a method for preparing a dan hong for injection, which relates to the method for preparing a dan hong preparation and aims to solve the problems in the conventional methods that a salvianolic acid B and hydroxysafflor yellow A cannot be completely extracted and that the prepared dan hong injections are inconvenient to transport and store. The dan hong for the injection of the invention is extracted by a proportioning and standing step and a filtering and freeze-drying step. The method has the advantages of achieving the high extraction efficiency of the salvianolic acid B and the hydroxysafflor yellow A; and it is convenient to store and transport the prepared dan hong for the injection.
Description
Patent application of the present invention is to be 200710144744.0 by application number, and the applying date is December in 2007 04 day, and denomination of invention is divided an application for the patent of invention of " extracting method of salvianolic acid B and S-A Hydroxysafflor yellow A and the preparation method of Danhong for injection ".
Technical field
The present invention relates to the preparation method of preparation containing red sange root and safflower.
Background technology
The DANHONG ZHUSHEYE of in " national drug standards (trying) promulgation part ", being announced be a kind of fine clinical efficacy is arranged, use existing two more than ten years history traditional Chinese patent medicine, be mainly used in the important emergent treatment of cardiovascular and cerebrovascular vessel, common have coronary heart disease, an angina pectoris etc., and the thoracic obstruction that can also treat due to the congestion obturation is an apoplexy etc.The method of existing salvianolic acid B that extracts and S-A Hydroxysafflor yellow A exists to be extracted not thorough to salvianolic acid B and S-A Hydroxysafflor yellow A.And adopt technique for extracting mixed in existing DANHONG ZHUSHEYE (ministry standard WS-11220 (ZD-1220)-2002) preparation process, the active constituent content that extracts is low, and what prepare is aqueous injection, because it is oxygenous in the aqueous solution, so easy oxidation Decomposition of salvianolic acid B wherein and S-A Hydroxysafflor yellow A, color can deepen and produce precipitation after the long term storage, poor stability, and the transportation of aqueous injection and storage are inconvenient.
Summary of the invention
The present invention thoroughly and in the preparation DANHONG ZHUSHEYE process does not adopt technique for extracting mixed for the extracting method that solves existing salvianolic acid B and S-A Hydroxysafflor yellow A exists to salvianolic acid B and S-A Hydroxysafflor yellow A extraction, the active constituent content that extracts is low, color can deepen and produce precipitation after the long term storage, and the problem of the poor stability of the DANHONG ZHUSHEYE of preparing, transportation and storage inconvenience, and provide the preparation method of Danhong for injection.
The extracting method of salvianolic acid B of the present invention carries out as follows: one, add 8～18 times of salvia piece quality to the red rooted salvia decoction pieces earlier, mass concentration is that 35%～60% ethanol and volume are ethanol volume 1 ‰～4 ‰, concentration is the soak with hydrochloric acid 1～2 hour of 1mol/L, reflux, extract, is 1.5～3 hours then, leach danshen solution, add 6～16 times of medicinal residues quality to medicinal residues again, mass concentration is that 35%～60% ethanol and volume are ethanol volume 1 ‰～4 ‰, concentration is the hydrochloric acid of 1mol/L, reflux, extract, 1～2 hour, leach danshen solution, the danshen solution that merges extracted twice, to become relative density be 1.16～1.24 Radix Salviae Miltiorrhizae clear paste to concentrating under reduced pressure again; Two, the water that adds 3～5 times of Radix Salviae Miltiorrhizae clear paste weight in the Radix Salviae Miltiorrhizae clear paste, limit add the waterside and stir, and leave standstill under the room temperature 12～24 hours, refilter, and it is 2.8～3.2 that Radix Salviae Miltiorrhizae filtrate is regulated pH value with hydrochloric acid, obtains Radix Salviae Miltiorrhizae acidify filtrate; Three, with the macroporous adsorptive resins pH value be 2.8～3.2 hcl acidifying, the Radix Salviae Miltiorrhizae acidify filtrate that step 2 is obtained is splined on the macroporous absorption post, with 5～7 times of resin volume pH value is 2.8～3.2 hydrochloric acid flushing impurity, the reuse mass concentration is 35%～55% ethanol elution, collect the Radix Salviae Miltiorrhizae eluent of 1.5～2.5 times of resin volumes, the pH value of regulating the Radix Salviae Miltiorrhizae eluent with sodium hydroxide solution is 4.0～4.2, is evaporated to relative density and is 1.08～1.25 salvianolic acid clear paste; Promptly obtain salvianolic acid B.
The extracting method of S-A Hydroxysafflor yellow A of the present invention carries out as follows: one, earlier add the water logging bubble 20～40 minutes that quality is 16～20 times of Flos Carthami quality to Flos Carthami, decocted 20～40 minutes, leach the Flos Carthami medicinal liquid, adding quality to medicinal residues again is the water of 14～18 times of medicinal residues quality, decocted 20～40 minutes, leach the Flos Carthami medicinal liquid, merge the Flos Carthami medicinal liquid that leaches for twice, be cooled to room temperature; Two, the Flos Carthami medicinal liquid is regulated pH value to 1.9～2.2 with hydrochloric acid, leaves standstill 6～24 hours, refilters, and obtains Flos Carthami acidify filtrate; Three, with the macroporous adsorptive resins pH value be 1.9～2.2 hcl acidifying, the Flos Carthami acidify filtrate that step 2 is obtained is splined on the macroporous absorption post, with 6～8 times of resin volume pH value is 1.9～2.2 hydrochloric acid flushing impurity, the reuse mass concentration is 8%～15% ethanol elution, collect the Flos Carthami eluent of 4.5～6.0 times of resin volumes, the pH value of regulating the Flos Carthami eluent with sodium hydroxide solution is 4.0～4.2, is evaporated to relative density and is 1.08～1.25 Hydroxy Carthamus yellow clear paste; Promptly get S-A Hydroxysafflor yellow A.
The method that salvianolic acid B that extracts with said method and S-A Hydroxysafflor yellow A prepare Danhong for injection is carried out as follows: be salvianolic acid B and the S-A Hydroxysafflor yellow A that 3: 1 ratio said method extracts according to Radix Salviae Miltiorrhizae and Flos Carthami medical material weight ratio one,, it is 75%～99% that adding water for injection makes the water content that is mixed with the DANHONG medicinal liquid and makes the DANHONG medicinal liquid, stirring the pH value of regulating the DANHONG medicinal liquid with sodium hydroxide solution in the back is 4.0～4.5, leaves standstill under 0～10 ℃ condition 12～48 hours; Two, earlier behind the filtering with microporous membrane with 0.22 μ m or 0.45 μ m, the Millipore ultrafiltration post that passes through the molecular weight that dams again and be 30K or 50K carries out ultrafiltration, with packing of DANHONG filtrate and lyophilizing; Promptly obtain Danhong for injection.
The preparation method of the extracting method of salvianolic acid B of the present invention, the extracting method of S-A Hydroxysafflor yellow A and Danhong for injection has the following advantages:
1, Radix Salviae Miltiorrhizae adopts 35%～60% ethanol to add the hydrochloric acid reflux extraction, has prevented the decomposes of effective ingredient salvianolic acid B in aqueous solution effectively, and extracted cmpletely that extraction ratio is 85%～95%, is 1.5～3 times of existing method.
2, the S-A Hydroxysafflor yellow A extraction ratio is 85%～95%, is 1.1～2.4 times of existing method.
3, the refining water lotion of taking of Radix Salviae Miltiorrhizae filters earlier, and back adjust pH passes through macroporous adsorptive resins again, has prevented that effectively effective ingredient from being filtered, and makes the content of effective monomer component salvianolic acid B and the rate of transform all more than 80%.
4, when the macroporous resin of Radix Salviae Miltiorrhizae and Flos Carthami is refining, the method for sour water flushing impurity has reduced loss of active ingredients effectively when all having adopted macroporous resin to use preceding acidify, eluting.
5, the macroporous adsorbent resin cost that preparation technology of the present invention adopted is low, in this preparation process the adsorption rate height, elute effect is good, regeneration is easy, long service life, and is reusable at least more than 20 times.
6, the molecular weight that dams that preparation technology of the present invention adopted is that the Millipore ultrafiltration post of 30K or 50K both can thoroughly have been removed impurity, antibacterial and the pyrogen in the medicinal liquid effectively, can keep effective ingredient effectively again.
7, preparation technology's operating process of the present invention is fairly simple, easy, efficient is high, cost is low, is particularly suitable for suitability for industrialized production.
8, salvianolic acid B and two monomer effective ingredient of S-A Hydroxysafflor yellow A index are adopted in product active constituent content control of the present invention, adopt high effective liquid chromatography for measuring, assay method is accurate, simple, stable, make that effective ingredient detection and control in process of production is all highly stable, the two content is aggregated in more than 60%.
9, the present invention extracts salvianolic acid B and S-A Hydroxysafflor yellow A respectively according to their differences of physical properties, salvianolic acid B that extracts and S-A Hydroxysafflor yellow A be the extraction ratio height not only, the purity of salvianolic acid B has also improved 40%～100%, and S-A Hydroxysafflor yellow A purity has also improved 30%～50%.
10, existing DANHONG injection water injection, because oxygenous in the aqueous solution, so the easy oxidation Decomposition of salvianolic acid B wherein and S-A Hydroxysafflor yellow A, color can deepen and produce precipitation after the long term storage, drug failure, and also aqueous injection is not easy to transportation.
The specific embodiment
The specific embodiment one: the extracting method of the salvianolic acid B of present embodiment carries out as follows: one, add 8～18 times of salvia piece quality to the red rooted salvia decoction pieces earlier, mass concentration is that 35%～60% ethanol and volume are ethanol volume 1 ‰～4 ‰, concentration is the soak with hydrochloric acid 1～2 hour of 1mol/L, reflux, extract, is 1.5～3 hours then, leach danshen solution, add 6～16 times of medicinal residues quality to medicinal residues again, mass concentration is that 35%～60% ethanol and volume are ethanol volume 1 ‰～4 ‰, concentration is the hydrochloric acid of 1mol/L, reflux, extract, 1～2 hour, leach danshen solution, the danshen solution that merges extracted twice, to become relative density be 1.16～1.24 Radix Salviae Miltiorrhizae clear paste to concentrating under reduced pressure again; Two, the water that adds 3～5 times of Radix Salviae Miltiorrhizae clear paste weight in the Radix Salviae Miltiorrhizae clear paste, limit add the waterside and stir, and leave standstill under the room temperature 12～24 hours, refilter, and it is 2.8～3.2 that Radix Salviae Miltiorrhizae filtrate is regulated pH value with hydrochloric acid, obtains Radix Salviae Miltiorrhizae acidify filtrate; Three, with the macroporous adsorptive resins pH value be 2.8～3.2 hcl acidifying, the Radix Salviae Miltiorrhizae acidify filtrate that step 2 is obtained is splined on the macroporous absorption post, with 5～7 times of resin volume pH value is 2.8～3.2 hydrochloric acid flushing impurity, the reuse mass concentration is 35%～55% ethanol elution, collect the Radix Salviae Miltiorrhizae eluent of 1.5～2.5 times of resin volumes, the pH value of regulating the Radix Salviae Miltiorrhizae eluent with sodium hydroxide solution is 4.0～4.2, is evaporated to relative density and is 1.08～1.25 salvianolic acid clear paste; Promptly obtain salvianolic acid B.
In the present embodiment relative density of the Radix Salviae Miltiorrhizae clear paste of step 1 be under 40～60 ℃ the condition Radix Salviae Miltiorrhizae clear paste with respect to the density of water; The relative density of the salvianolic acid clear paste of step 3 be under 40～60 ℃ the condition salvianolic acid clear paste with respect to the density of water.
The specific embodiment two: the difference of the present embodiment and the specific embodiment one is: earlier adding 12～14 times of salvia piece quality, mass concentration to the red rooted salvia decoction pieces in the step 1 is that 45%～55% ethanol and volume are that ethanol volume 2 ‰～3 ‰, concentration are the soak with hydrochloric acid 1.2～1.8 hours of 1mol/L, and reflux, extract, is 2～2.5 hours then.Other step and parameter are identical with the specific embodiment one.
The specific embodiment three: the difference of the present embodiment and the specific embodiment one is: earlier adding 13 times of salvia piece quality, mass concentration to the red rooted salvia decoction pieces in the step 1 is that 50% ethanol and volume are that ethanol volume 2.5 ‰, concentration are the soak with hydrochloric acid 1.5 hours of 1mol/L, and reflux, extract, is 2.2 hours then.Other step and parameter are identical with the specific embodiment one.
The specific embodiment four: the difference of the present embodiment and the specific embodiment one is: adding 10～12 times of medicinal residues quality, mass concentration to medicinal residues again in the step 1 is that 48%～52% ethanol and volume are that ethanol volume 1.5 ‰～3.5 ‰, concentration are the hydrochloric acid of 1mol/L, reflux, extract, 1.2～1.8 hours.Other step and parameter are identical with the specific embodiment one.
The specific embodiment five: the difference of the present embodiment and the specific embodiment one is: adding 11 times of medicinal residues quality, mass concentration to medicinal residues again in the step 1 is that 51% ethanol and volume are that ethanol volume 2 ‰, concentration are the hydrochloric acid of 1mol/L, reflux, extract, 1.5 hours.Other step and parameter are identical with the specific embodiment one.
The specific embodiment six: present embodiment with the difference of the specific embodiment one is: to become relative density be 1.18～1.22 Radix Salviae Miltiorrhizae clear paste to the danshen solution concentrating under reduced pressure in the step 1.Other step and parameter are identical with the specific embodiment one.
The specific embodiment seven: present embodiment with the difference of the specific embodiment one is: to become relative density be 1.20 Radix Salviae Miltiorrhizae clear paste to the danshen solution concentrating under reduced pressure in the step 1.Other step and parameter are identical with the specific embodiment one.
The specific embodiment eight: the difference of the present embodiment and the specific embodiment one is: the water that adds 4 times of Radix Salviae Miltiorrhizae clear paste weight in the step 2 in the Radix Salviae Miltiorrhizae clear paste.Other step and parameter are identical with the specific embodiment one.
The specific embodiment nine: the difference of the present embodiment and the specific embodiment one is: the Radix Salviae Miltiorrhizae clear paste left standstill 15～21 hours after adding water in the step 2.Other step and parameter are identical with the specific embodiment one.
The specific embodiment ten: the difference of the present embodiment and the specific embodiment one is: the Radix Salviae Miltiorrhizae clear paste left standstill 17～19 hours after adding water in the step 2.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 11: the difference of the present embodiment and the specific embodiment one is: the Radix Salviae Miltiorrhizae clear paste left standstill 18 hours after adding water in the step 2.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 12: the difference of the present embodiment and the specific embodiment one is: Radix Salviae Miltiorrhizae filtrate is 3.0 with hydrochloric acid adjusting pH value in the step 2.Other step and parameter are identical with the specific embodiment one.
The mass concentration of hydrochloric acid is 3%～10% in the present embodiment.
The specific embodiment 13: the difference of the present embodiment and the specific embodiment one is: in the step 3 be 3.0 hcl acidifying with the macroporous adsorptive resins pH value.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 14: the difference of the present embodiment and the specific embodiment one is: the hydrochloric acid with 6 times of column volume pH value 3.0 in the step 3 washes impurity.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 15: the difference of the present embodiment and the specific embodiment one is: the reuse mass concentration is 40%～50% ethanol elution in the step 3.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 16: the difference of the present embodiment and the specific embodiment one is: the reuse mass concentration is 55% ethanol elution in the step 3.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 17: the difference of the present embodiment and the specific embodiment one is: the pH value with sodium hydroxide solution adjusting Radix Salviae Miltiorrhizae eluent in the step 3 is 4.1.Other step and parameter are identical with the specific embodiment one.
The mass concentration of sodium hydroxide solution is 3%～10% in the present embodiment.
The specific embodiment 18: the difference of the present embodiment and the specific embodiment one is: be evaporated to relative density in the step 3 and be 1.16～1.20 salvianolic acid clear paste.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 19: the difference of the present embodiment and the specific embodiment one is: be evaporated to relative density in the step 3 and be 1.18 salvianolic acid clear paste.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 20: the difference of the present embodiment and the specific embodiment one is: the model of macroporous adsorbent resin is HZ801, AB-8 or D101 in the step 3.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 21: the difference of the present embodiment and the specific embodiment one is: go up the sample flow velocity in the step 3 and be 1 resin volume/hour～1.5 resin volumes/hour.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 22: the difference of the present embodiment and the specific embodiment one is: in the step 3 flow velocity of flushing impurity be 1 resin volume/hour～1.5 resin volumes/hour.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 23: the difference of the present embodiment and the specific embodiment one is: in the step 3 elution flow rate be 1 resin volume/hour～1.5 resin volumes/hour.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 24: the difference of the present embodiment and the specific embodiment one is: the Radix Salviae Miltiorrhizae eluent of collecting 2 times of resin volumes in the step 3.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 25: the difference of the present embodiment and the specific embodiment one is: the weight of macroporous adsorbent resin is 2 times of Radix Salviae Miltiorrhizae weight in the step 3.Other step and parameter are identical with the specific embodiment one.
The specific embodiment 26: the extracting method of the S-A Hydroxysafflor yellow A of present embodiment carries out as follows: one, earlier add the water logging bubble 20～40 minutes that quality is 16～20 times of Flos Carthami quality to Flos Carthami, decocted 20～40 minutes, leach the Flos Carthami medicinal liquid, adding quality to medicinal residues again is the water of 14～18 times of medicinal residues quality, decocted 20～40 minutes, leach the Flos Carthami medicinal liquid, merge the Flos Carthami medicinal liquid that leaches for twice, be cooled to room temperature; Two, the Flos Carthami medicinal liquid is regulated pH value to 1.9～2.2 with hydrochloric acid, leaves standstill 6～24 hours, refilters, and obtains Flos Carthami acidify filtrate; Three, with the macroporous adsorptive resins pH value be 1.9～2.2 hcl acidifying, the Flos Carthami acidify filtrate that step 2 is obtained is splined on the macroporous absorption post, with 6～8 times of resin volume pH value is 1.9～2.2 hydrochloric acid flushing impurity, the reuse mass concentration is 8%～15% ethanol elution, collect the Flos Carthami eluent of 4.5～6.0 times of resin volumes, the pH value of regulating the Flos Carthami eluent with sodium hydroxide solution is 4.0～4.2, is evaporated to relative density and is 1.08～1.25 Hydroxy Carthamus yellow clear paste; Promptly get S-A Hydroxysafflor yellow A.
In the present embodiment relative density of the Hydroxy Carthamus yellow clear paste of step 3 be under 40～60 ℃ the condition Hydroxy Carthamus yellow clear paste with respect to the density of water.
The specific embodiment 27: the difference of the present embodiment and the specific embodiment 26 is: earlier add the water logging bubble 25～35 minutes that quality is 17～19 times of Flos Carthami quality to Flos Carthami in the step 1, decocted 25～35 minutes.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 28: the difference of the present embodiment and the specific embodiment 26 is: earlier add the water logging bubble 30 minutes that quality is 18 times of Flos Carthami quality to Flos Carthami in the step 1, decocted 30 minutes.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 29: the difference of the present embodiment and the specific embodiment 26 is: adding quality to medicinal residues again in the step 1 is the water of 15～17 times of medicinal residues quality, decocts 25～30 minutes.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 30: the difference of the present embodiment and the specific embodiment 26 is: adding quality to medicinal residues again in the step 1 is 16 times of medicinal residues quality, decocts 28 minutes.Other step and parameter are identical with the specific embodiment 26.
Specific embodiment hentriaconta-: the difference of the present embodiment and the specific embodiment 26 is: the Flos Carthami medicinal liquid is regulated pH value to 2.0～2.1 with hydrochloric acid in the step 2, leaves standstill 10～20 hours.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 32: the difference of the present embodiment and the specific embodiment 26 is: the Flos Carthami medicinal liquid is regulated pH value to 2.0 with hydrochloric acid in the step 2, leaves standstill 15 hours.Other step and parameter are identical with the specific embodiment 26.
The hydrochloric acid mass concentration of present embodiment is 3%～10%.
The specific embodiment 33: the difference of the present embodiment and the specific embodiment 26 is: in the step 3 be 2.1 hcl acidifying with the macroporous adsorptive resins pH value.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 34: the difference of the present embodiment and the specific embodiment 26 is: the hydrochloric acid with 7 times of resin volume pH value 2.0 in the step 3 washes impurity.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 35: the difference of the present embodiment and the specific embodiment 26 is: the reuse mass concentration is 10%～12% ethanol elution in the step 3.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 36: the difference of the present embodiment and the specific embodiment 26 is: the reuse mass concentration is 11% ethanol elution in the step 3.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 37: the difference of the present embodiment and the specific embodiment 26 is: the pH value with sodium hydroxide solution adjusting Flos Carthami eluent in the step 3 is 4.1.Other step and parameter are identical with the specific embodiment 26.
The mass concentration of the sodium hydroxide solution of present embodiment is 3%～10%.
The specific embodiment 38: the difference of the present embodiment and the specific embodiment 26 is: be evaporated to relative density in the step 3 and be 1.12～1.20 Hydroxy Carthamus yellow clear paste.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 39: the difference of the present embodiment and the specific embodiment 26 is: be evaporated to relative density in the step 3 and be 1.16 Hydroxy Carthamus yellow clear paste.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 40: the difference of the present embodiment and the specific embodiment 26 is: the model of macroporous adsorbent resin is X-5 or D4020 in the step 3.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 41: the difference of the present embodiment and the specific embodiment 26 is: go up the sample flow velocity in the step 3 and be 1 resin volume/hour～1.5 resin volumes/hour.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 42: the difference of the present embodiment and the specific embodiment 26 is: in the step 3 flow velocity of flushing impurity be 1 resin volume/hour～1.5 resin volumes/hour.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 43: the difference of the present embodiment and the specific embodiment 26 is: in the step 3 elution flow rate be 1 resin volume/hour～1.5 resin volumes/hour.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 44: the difference of the present embodiment and the specific embodiment 26 is: the Flos Carthami eluent of collecting 5 times of resin volumes in the step 3.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 45: the difference of the present embodiment and the specific embodiment 26 is: the weight of macroporous adsorbent resin is 4 times of Flos Carthami weight in the step 3.Other step and parameter are identical with the specific embodiment 26.
The specific embodiment 46: the S-A Hydroxysafflor yellow A that present embodiment is extracted with the salvianolic acid B and the specific embodiment 26 of the specific embodiment one extraction prepares the method for Danhong for injection to carry out as follows: one, according to Radix Salviae Miltiorrhizae and Flos Carthami medical material weight ratio is that 3: 1 ratio is got the S-A Hydroxysafflor yellow A that salvianolic acid B that the specific embodiment one extracts and the specific embodiment 26 are extracted, it is 75%～99% that adding water for injection makes the water content that is mixed with the DANHONG medicinal liquid and makes the DANHONG medicinal liquid, stirring the pH value of regulating the DANHONG medicinal liquid with sodium hydroxide solution in the back is 4.0～4.5, leaves standstill under 0～10 ℃ condition 12～48 hours; Two, earlier behind the filtering with microporous membrane with 0.22 μ m or 0.45 μ m, the Millipore ultrafiltration post that passes through the molecular weight that dams again and be 30K or 50K carries out ultrafiltration, with packing of DANHONG filtrate and lyophilizing; Promptly obtain Danhong for injection.
The specific embodiment 47: the difference of the present embodiment and the specific embodiment 46 is: the water content that makes the DANHONG medicinal liquid in the step 1 is 80%～95%.Other step and parameter are identical with the specific embodiment 46.
The specific embodiment 48: the difference of the present embodiment and the specific embodiment 46 is: the water content that makes the DANHONG medicinal liquid in the step 1 is 85%～90%.Other step and parameter are identical with the specific embodiment 46.
The specific embodiment 49: the difference of the present embodiment and the specific embodiment 46 is: the water content that makes the DANHONG medicinal liquid in the step 1 is 88%.Other step and parameter are identical with the specific embodiment 46.
The specific embodiment 50: the difference of the present embodiment and the specific embodiment 46 is: the pH value with sodium hydroxide solution adjusting DANHONG medicinal liquid in the step 1 is 4.2～4.4.Other step and parameter are identical with the specific embodiment 46.
The mass concentration of the sodium hydroxide solution of present embodiment is 3%～10%.
The specific embodiment 51: the difference of the present embodiment and the specific embodiment 46 is: the pH value with sodium hydroxide solution adjusting DANHONG medicinal liquid in the step 1 is 4.3.Other step and parameter are identical with the specific embodiment 46.
The specific embodiment 52: the difference of the present embodiment and the specific embodiment 46 is: left standstill under 2～8 ℃ condition 18～30 hours in the step 1.Other step and parameter are identical with the specific embodiment 46.
The specific embodiment 53: the difference of the present embodiment and the specific embodiment 46 is: left standstill under 4～6 ℃ condition 25～28 hours in the step 1.Other step and parameter are identical with the specific embodiment 46.
The specific embodiment 54: the difference of the present embodiment and the specific embodiment 46 is: left standstill under 5 ℃ condition 27 hours in the step 1.Other step and parameter are identical with the specific embodiment 46.
The specific embodiment 55: the preparation method of the Danhong for injection of present embodiment is carried out as follows: one, extract salvianolic acid B; Two, extract S-A Hydroxysafflor yellow A; Three, be that 3: 1 ratio is got the S-A Hydroxysafflor yellow A that salvianolic acid B that step 1 extracts and step 2 are extracted according to Radix Salviae Miltiorrhizae and Flos Carthami medical material weight ratio, it is 85% that adding water for injection makes the water content that is mixed with the DANHONG medicinal liquid and makes the DANHONG medicinal liquid, stirring the pH value of regulating the DANHONG medicinal liquid with sodium hydroxide solution in the back is 4.2, leaves standstill under 5 ℃ condition 40 hours; Four, earlier behind the filtering with microporous membrane with 0.22 μ m, the Millipore ultrafiltration post that passes through the molecular weight that dams again and be 30K carries out ultrafiltration, with packing of DANHONG filtrate and lyophilizing; Promptly obtain Danhong for injection.
The method that the present embodiment step 1 is extracted salvianolic acid B is: one, add 16 times of salvia piece quality to the red rooted salvia decoction pieces earlier, mass concentration is that 50% ethanol and volume are ethanol volume 2 ‰, concentration is the soak with hydrochloric acid 1.5 hours of 1mol/L, reflux, extract, is 2 hours then, leach danshen solution, add 12 times of medicinal residues quality to medicinal residues again, mass concentration is that 55% ethanol and volume are ethanol volume 2 ‰, concentration is the hydrochloric acid of 1mol/L, reflux, extract, 1.5 hours, leach danshen solution, the danshen solution that merges extracted twice, to become relative density be 1.18 Radix Salviae Miltiorrhizae clear paste to concentrating under reduced pressure again; Two, the water that adds 4 times of Radix Salviae Miltiorrhizae clear paste weight in the Radix Salviae Miltiorrhizae clear paste, limit add the waterside and stir, and leave standstill under the room temperature 20 hours, refilter, and it is 2.9 that Radix Salviae Miltiorrhizae filtrate is regulated pH value with hydrochloric acid, obtains Radix Salviae Miltiorrhizae acidify filtrate; Three, it with the macroporous adsorptive resins pH value 2.9 hcl acidifying, the Radix Salviae Miltiorrhizae acidify filtrate that step 2 is obtained is splined on the macroporous absorption post, last sample flow velocity be 1 resin volume/hour～1.5 resin volumes/hour, hydrochloric acid flushing impurity with 6 times of resin volume pH value 2.9, elution flow rate be 1 resin volume/hour～1.5 resin volumes/hour, 2 times of column volumes of reuse, mass concentration is 50% ethanol elution, elution flow rate be 1 resin volume/hour～1.5 resin volumes/hour, collect the Radix Salviae Miltiorrhizae eluent of 2.0 times of resin volumes, the pH value of regulating the Radix Salviae Miltiorrhizae eluent with sodium hydroxide solution is 4.1, is evaporated to relative density and is 1.16 salvianolic acid clear paste; Promptly obtain salvianolic acid B.
The method that the present embodiment step 2 is extracted S-A Hydroxysafflor yellow A is: one, add the water logging bubble 30 minutes that quality is 18 times of Flos Carthami quality to Flos Carthami earlier, decocted 30 minutes, leach the Flos Carthami medicinal liquid, add the water logging bubble 35 minutes that quality is 16 times of medicinal residues quality to medicinal residues again, decocted 35 minutes, leach the Flos Carthami medicinal liquid, merge the Flos Carthami medicinal liquid that leaches for twice, be cooled to room temperature; Two, the Flos Carthami medicinal liquid is regulated pH value to 2.0 with hydrochloric acid, leaves standstill 18 hours, refilters, and obtains Flos Carthami acidify filtrate; Three, it with the macroporous adsorptive resins pH value 2.0 hcl acidifying, the Flos Carthami acidify filtrate that step 2 is obtained be splined on go up on the macroporous absorption post sample flow velocity be 1 resin volume/hour～1.5 resin volumes/hour, hydrochloric acid flushing impurity with 7 times of column volume pH value 2.0, elution flow rate be 1 resin volume/hour～1.5 resin volumes/hour, the reuse mass concentration is 12% ethanol elution, elution flow rate be 1 resin volume/hour～1.5 resin volumes/hour, collect the Flos Carthami eluent of 5.0 times of resin volumes, the pH value of regulating the Flos Carthami eluent with sodium hydroxide solution is 4.1, is evaporated to relative density and is 1.16 Hydroxy Carthamus yellow clear paste; Promptly get S-A Hydroxysafflor yellow A.
The Danhong for injection that present embodiment is made carries out following pharmacodynamics test research:
1, Danhong for injection is to dog myocardial infarction model and hemodynamic influence due to the coronary ligation
Purpose: observe the Danhong for injection administration to dog myocardial infarction and hemodynamic influence due to the coronary ligation.
Method: get 30 of healthy adult domesticated dogs, male and female half and half, body weight 13.6 ± 1.25kg is divided into 5 groups at random by body weight, is respectively model group, the basic, normal, high dosage group of Danhong for injection and DANHONG ZHUSHEYE positive controls.During test with dog with pentobarbital sodium 30mgkg
-1Anesthesia, tracheal intubation connects artificial respirator, and is subcutaneous with needle electrode insertion extremity and front.Open breast along left border of sternum 3-4 intercostal, fully expose heart.Cut off pericardium and make the pericardium hammock.With 1/3 place on No. 0 silk thread ligation ramus descendens anterior arteriae coronariae sinistrae, each group administration respectively behind the ligation 15min, the basic, normal, high dosage group of Danhong for injection dosage is respectively 3mgkg
-1, 6mgkg
-1, and 12mgkg
-1, positive controls gives DANHONG ZHUSHEYE, and dosage is 4mlkg
-1, model group gives 0.9% sodium chloride injection of respective volume.With 15min, 30min, 60min, 90min, 120min, 180min epicardial electrogram EKG before the ligation of polygraph record, behind the stable back of ligation, administration, and calculate ∑-ST and NST.With 15min, 30min, 60min, 90min, 120min, 180min hemodynamics physiological parameter before polygraph, the ligation of doppler flowmeter detection record, after the stable back of ligation and the administration.Separate carotid artery, extract arterial blood, get Coronary vein blood through external jugular vein intubate to coronary sinus vein and survey oxygen content with oximeter.The 2ml that draws blood simultaneously measures the content of serum lactate dehydrogenase (SLD) (LDH), creatine phosphokinase (CK) with automatic biochemistry analyzer.3h behind the medicine, dirty the weighing of coring, myocardial infarction area is measured in TTC dyeing.
The result: (∑-ST) and myocardial ischemia scope (NST): behind the coronary ligation, each organizes dog ST section and obviously raises (1) degree of myocardial ischemia.With the same period model group compare, ∑-ST and NST all have reduction behind each dosage group of Danhong for injection and the positive control drug DANHONG ZHUSHEYE medicine, behind the high dose group medicine behind ∑-ST of 30～90min, the medicine NST of 60～120min significantly reduce, with model group significant difference (P＜0.05) is arranged relatively, though other times point no difference of science of statistics all has reduction trend; In behind the dosage group medicine behind the ∑-ST, medicine of 60min the NST of 60～90min significantly reduce, with model group significant difference (P＜0.05) is arranged relatively; Low dose group ∑-ST and NST all have reduction trend, but no difference of science of statistics; 30min, 60～90min have obvious inhibitory action to the increase of raising with NST of ∑-ST respectively behind the DANHONG ZHUSHEYE positive controls medicine, with model group significant difference (P＜0.05) are arranged relatively.Compare with positive controls, each time point ∑-ST and NST there was no significant difference behind the basic, normal, high dosage group of the Danhong for injection medicine, but the Danhong for injection high dose has further reduction ∑-ST and NST trend, and concrete experimental data is as shown in Table 1 and Table 2.
Table 1 Danhong for injection to acute myocardial ischemia epicardial electrogram ∑-ST (
Mv) influence
Annotate: 1. n=6; 2.
*P＜0.05,
*Compare with model group P＜0.01.
Table 2 Danhong for injection is to coronary artery ligation dog myocardial ischemia scope
Influence
Annotate: 1. n=6; 2.
*P＜0.05,
*Compare with model group P＜0.01; 3.
ΔP＜0.05,
The Δ ΔCompare with the preceding value of medicine P＜0.01.
(2) myocardial infarct size: 195min respectively organizes dog and tangible myocardial infarction all occurs behind the coronary ligation, compares with model group, and each dosage of positive control drug and Danhong for injection all obviously dwindles myocardial infarct size.Dosage group myocardial infarction district area accounts for left ventricle and whole-heartedly ratio is low by 2.68% and 6.36% than model group respectively in the Danhong for injection, and high dose group reduces by 3.06% and 6.55% respectively, and obvious statistical significance (P＜0.05) is all arranged; The Danhong for injection low dose group reduces by 1.29% and 5.15% respectively, and reduction trend is arranged, but does not have tangible statistical significance; Positive controls myocardial infarction district area accounts for left ventricle and ratio whole-heartedly is low by 2.18% and 5.75% than model group respectively, and obvious statistical significance (P＜0.05) is arranged.Compare with positive controls, the basic, normal, high dosage group of Danhong for injection myocardial infarction district area there was no significant difference, but the Danhong for injection high dose has further reduction myocardial infarction district area trend, and concrete experimental data is as shown in table 3.
Table 3 Danhong for injection is to coronary artery ligation dog myocardial infarct size
Influence
Annotate: 1. n=6; 2.
*P＜0.05,
*Compare with model group P＜0.01.
(3) creatine kinase (CK) and lactic acid dehydrogenase (LDH): each treated animal serum CK and LDH obviously raise before than ligation after the coronary artery ligation.Though the 180min sero-enzyme also has rising behind each dosage group of Danhong for injection and the positive controls medicine, the amplitude that raises all has reduction in various degree.Compare Danhong for injection 3mgkg with model group
-1180min has certain inhibition trend to the rising of sero-enzyme behind the medicine, but there was no significant difference; 6mgkg
-1The activity that can obviously suppress Serum LDH, CK with the 12mgkg-1 administration raise (P＜0.05 or P＜0.01).Also can significantly suppress the rising of Serum LDH, CK behind the DANHONG ZHUSHEYE medicine, significant difference (P＜0.05) relatively be arranged with model group.Compare with positive controls, the basic, normal, high dosage group of Danhong for injection suppresses the activity rising effect there was no significant difference of Serum LDH, CK, but the Danhong for injection high dose group can further suppress the activity rising degree of LDH, CK, and concrete experimental data is shown in table 4 and table 5.
Table 4 Danhong for injection to coronary artery ligation dog serum lactic acid dehydrogenase (
U/L) influence
Annotate: 1. n=6; 2.
*P＜0.05,
*Compare with model group P＜0.01.
Table 5 Danhong for injection to coronary artery ligation dog serum creatine creatase (
U/L) influence
Annotate: 1. n=6; 2.
*P＜0.05,
*Compare with model group P＜0.01.
(4) left ventricular pressure (LVP), left ventricular end diastolic are pressed (LVEDP) and the maximum rate of change (dp/dt of left ventricular pressure
Max): compare with model group, 15min administration after each dosage of Danhong for injection and the positive controls ligation, LVP does not see variation; For LVEDP, middle and high dosage group of Danhong for injection and the DANHONG ZHUSHEYE positive controls left ventricular diastolic end voltage rise height that decline causes to myocardial contractility has significant reduction effect, 90～180min and model group relatively have significant difference (P＜0.05 or P＜0.01) behind the medicine, after the administration of Danhong for injection low dosage left ventricular diastolic end voltage rise height there is certain inhibition trend, but there was no significant difference, concrete experimental data is shown in table 6, table 7 and table 8.
Table 6 Danhong for injection is to dog dp/dt
MaxInfluence
Annotate:
*P＜0.05,
*Compare with model group P＜0.01.
Table 7 Danhong for injection is to the influence of dog LVEDP
Annotate:
*P＜0.05,
*Compare with model group P＜0.01.
Table 8 Danhong for injection is to the influence of dog LVP
Annotate:
*P＜0.05,
*1＜0.01, compare with model group.
For dp/dt
Max, with model group relatively, middle and high dosage group of Danhong for injection and DANHONG ZHUSHEYE positive controls all have the increase effect, 90～180min and model group relatively have significant difference (P＜0.05) behind the medicine, after the administration of Danhong for injection low dosage to dp/dt
MaxIncrease trend is arranged, but there was no significant difference.
Compare the basic, normal, high dosage group of Danhong for injection LVP, LVEDP and dp/dt with positive controls
MaxDifference is not obvious, but Danhong for injection high dose group LVEDP, dp/dt
MaxFurther reduction and increase trend are arranged respectively.
(5) aorta flow (CO) and coronary flow (CAF): compare with model group, behind the middle and high dosed administration of Danhong for injection, rate of change behind anesthetized dog CO and the CAF medicine there is the increase effect, respectively at 60～120min behind the medicine and 60～180min significant difference (P＜0.05) is arranged, though other times point no difference of science of statistics all has increase trend; Behind the Danhong for injection low dosage medicine behind CO and the CAF medicine rate of change increase trend is also arranged, but no difference of science of statistics.Behind the DANHONG ZHUSHEYE positive controls medicine 90～120min to CO and CAF medicine after rate of change be significantly increased effect, with model group significant difference (P＜0.05) is arranged relatively.Compare with positive controls, the basic, normal, high dosage group of Danhong for injection CO, CAF there was no significant difference, but the Danhong for injection high dose has further increase CO, CAF trend, and concrete experimental data is shown in table 9 and table 10.
Table 9 Danhong for injection is to the influence of dog CO
Annotate: 1. n=6; 2.
*P＜0.05,
*Compare with model group P＜0.01.
Table 10 Danhong for injection is to the influence of dog CAF
Annotate: 1. n=6; 2.
*P＜0.05,
*Compare with model group P＜0.01.
(6) arteriovenous blood oxygen content: compare with model group, the middle and high dosage group of Danhong for injection and DANHONG ZHUSHEYE positive controls 60min after administration begin, the atrerial venous oxygen content difference value obviously rises (P＜0.05 or P＜0.01), and wherein the Danhong for injection high dose group can reach 180min behind the medicine action time.The Danhong for injection low dose group has increase trend, but there was no significant difference.With positive controls relatively, each time point of the basic, normal, high dosage group of Danhong for injection atrerial venous oxygen content difference value there are no significant difference, but the Danhong for injection high dose group can further increase the atrerial venous oxygen content difference value, concrete experimental data is as shown in table 11.
Table 11 Danhong for injection is to the influence of dog atrerial venous oxygen content difference value
Annotate: 1. n=6; 2.
*P＜0.05,
*Compare with model group P＜0.01.
Conclusion: ∑-ST and NST raise behind (1) this test model dog coronary ligation, and Serum LDH and CK are active to be increased, and the 195min myocardial infarction area is obvious after the ligation, illustrates that model prepares successfully.
(2) Danhong for injection has significant protective effect to the dog myocardial ischemia, has effects such as the cardiovascular function of improvement, blood circulation promoting, increase atrerial venous oxygen content difference value, and its onset dosage is 3～6mgkg
-1Under this experimental condition, positive control drug DANHONG ZHUSHEYE and Danhong for injection 6mgkg
-1∑-ST, NST that dog myocardial infarction is caused raise, and Serum LDH, the active increase of CK and LVEDP raise tangible reduction effect is arranged, to dp/dt
Max, CO, CAF and atrerial venous oxygen content difference value have the increase effect, with model group significant difference (P＜0.05) arranged more all respectively; Danhong for injection 3mgkg
-1Above index all there is certain effect trend, but not obvious with the model group comparing difference; Danhong for injection 12mgkg
-1Can further improve dog myocardial ischemia index and dp/dt
Max, CO, CAF and arteriovenous blood oxygen content.Increase Danhong for injection effect with dosage presents certain dose-effect relationship, and 30min begins onset behind the medicine, and effective drug duration can reach 180min behind the medicine.
(3) compare Danhong for injection 6mgkg with positive control drug
-1Action effect is suitable with it.Compare Danhong for injection 12mgkg with DANHONG ZHUSHEYE
-1Though to ∑-ST, NST rising, Serum LDH, CK actively increase, LVEDP raises reduction effect with to the increase effect no difference of science of statistics of dp/dtmax, CO, CAF and atrerial venous oxygen content difference value, degree has further improvement; Danhong for injection 3mgkg
-1Above index there is certain effect trend, compare there was no significant difference with DANHONG ZHUSHEYE, but the effect degree is lighter.
(4) by above pharmacodynamic study results suggest, the effective initial dose of Danhong for injection clinical application is about 1.5～3mgkg
-1, recommend clinical plan to be about 90～180mg with dosage in human body body weight 60kg.
2, Danhong for injection is to the influence of focal brain ischemia-reperfusion injury in rats model
Purpose: observe the protective effect of Danhong for injection administration to focal brain ischemia-reperfusion injury in rats.
Method: get healthy male Wistar rat, after adaptability is fed a week, be divided into 6 groups at random: sham operated rats, model group, the basic, normal, high dosage group of Danhong for injection, and positive controls by body weight.Adopt bolt line blocked method (MCAO) preparation focal brain ischemia-reperfusion injury in rats model in improved Zea Longa ' the s middle cerebral artery, and behind ischemia 1.5h, pour into again.In the process of the test, the MCAO operative failure, modeling gets nowhere and the interior dead animal of 24h is all given it up, and deficiency is scheduled to the number person according to stochastic sampling principle polishing animal and modeling again, and guarantees that the number of animals of every group of modeling success is 8.Sham operated rats gives respective volume 0.9% sodium chloride injection, and basic, normal, high group of dosage of Danhong for injection is respectively 10mgkg
-1, 20mgkg
-1And 40mgkg
-1, positive controls gives DANHONG ZHUSHEYE, and dosage is 12mlkg
-1Each group is respectively at cerebral ischemia tail vein injection relative medicine at once.After cerebral ischemia 1.5h poured into 24h again, each treated animal carried out neurologic check, and broken end is got brain and measure ischemia side cerebral tissue Infarction volume after TTC dyeing then.
Result: compare with sham operated rats, the neurologic impairment sign is obvious behind the model group focal cerebral ischemia in rats 1.5h reperfusion injury 24h, the visible significantly milky infarction kitchen range of ischemia side cerebral tissue naked eyes, and with edema, ischemia vascellum laterale swelling simultaneously is more obvious, the visible significantly infarction kitchen range of TTC dyeing illustrates that model prepares successfully, satisfies this test requirements document.Compare with model group, the delayed ischemic neurological deficits of positive controls and each medication group ischemical reperfusion injury rat all has improvement, and the cerebral infarction volume obviously dwindles, and ischemia side degree of cerebral edema alleviates.The positive controls brain infarction area reduces 12%, and obvious statistical significance (P＜0.05) is arranged.Low dose group cerebral infarction volume reduces 5%, but does not have tangible statistical significance; Middle dosage group cerebral infarction volume reduces by 14%, and high dose group reduces by 18%, two group all obvious statistical significance (P＜0.01).With positive controls relatively, low, middle dosage group no significant difference, high dose group has significant difference (P＜0.05), and is more effective than Danhong Injection in Treating, concrete experimental data sees Table 12 and table 13.
The influence that table 12 Danhong for injection changes the rat neuroethology
Annotate: n=8;
*P＜0.05,
*Compare with model group P＜0.01.
Table 13 Danhong for injection is to the influence of rat cerebral infarction area
Annotate: n=8;
*P＜0.05,
*Compare with model group P＜0.01;
ΔCompare with the DANHONG ZHUSHEYE group P＜0.05.
Conclusion: the standard that scoring meets the model success is learned by (1) this test model group rat function of nervous system, and the visible obviously cerebral infarction kitchen range of TTC dyeing illustrates that model prepares successfully.Positive control drug can significantly improve cerebral ischemia.
(2) Danhong for injection 10mgkg
-1Damage is had some improvement, but statistically with the model group no significant difference.20mgkg
-1Focal brain ischemia-reperfusion injury in rats is had significant protective effect, can improve ischemia 1.5h and pour into neurologic impairment symptom behind the 24h again, significantly cerebral infarct volume alleviates ischemia side degree of cerebral edema.40mgkg
-1Can further reduce the brain injury degree, and good than the positive controls therapeutic effect.With the increase of dosage, the cerebral infarction volume reduces gradually, presents certain dose-effect relationship.
(3) compare Danhong for injection low dosage 10mgkg with the positive control drug DANHONG ZHUSHEYE
-1DeGrain, middle dosage 20mgkg
-1Curative effect is suitable with it; High dose 40mgkg
-1Can obviously improve the delayed ischemic neurological deficits of ischemical reperfusion injury rat, the cerebral infarction volume significantly dwindles, and ischemia side degree of cerebral edema alleviates, and is effective than Danhong Injection in Treating.
(4) by above pharmacodynamic study results suggest, the effective initial dose of Danhong for injection clinical application is about 1.7～3.3mgkg
-1, recommend the clinical treatment apoplexy to intend being about 100～200mg with dosage in human body body weight 60kg.
3, the influence of Danhong for injection chmice acute pulmonary infarction that ADP is brought out
Purpose: observe Danhong for injection repeatedly the tail administration to the influence of ADP induced mice acute pulmonary embolism.
Method: get 50 of healthy adult kunming mices, be divided into blank group (Veh), the basic, normal, high dosage group of Danhong for injection and positive controls, 10 every group, male and female half and half at random by body weight.Continuously the tail administration is 3 days, and the Veh group gives 0.9% sodium chloride injection of respective volume, and the Danhong for injection dosage is respectively 15,30 and 60mgkg
-1, positive controls gives DANHONG ZHUSHEYE, and dosage is 20mlkg
-11h tail vein injection ADP 0.25gkg after the last administration
-1, make the acute pulmonary embolism model, normal to mouse breathing behind the record injection derivant, extremity recover the required time of autonomic activities.
The result: compare with the Veh group, the positive controls mice recovers the autonomic activities required time and reduces 131s, and remarkable significant difference (P＜0.01) is arranged.The basic, normal, high dosage group of the Danhong for injection mice recovery required time of autonomic activities obviously shortens, and wherein low dose group shortens 98s, and middle and high dosage shortens 136s, 165s respectively, and remarkable significant difference (P＜0.01) is all arranged.Compare with positive controls, basic, normal, high dosage group does not all have obvious significant difference, and concrete experimental data sees Table 14.
Table 14 Danhong for injection to ADP cause the chmice acute pulmonary infarction influence (
S)
Annotate: n=10;
*Compare with the Veh group P＜0.01.
Conclusion: (1) Danhong for injection 15mgkg
-1Recover autonomic activities required time (P＜0.01), middle dosage 30mgkg after can significantly shortening the chmice acute pulmonary infarction that ADP brings out
-1With high dose 60mgkg
-1Also can obviously shorten and recover autonomic activities required time (P＜0.01).And with the increase of dosage, recover the autonomic activities required time after the chmice acute pulmonary infarction that ADP is brought out and shorten gradually, have tangible dose-effect relationship.
(2) compare with the positive control drug DANHONG ZHUSHEYE, the low dose group action effect is not remarkable, and middle and high dosage group curative effect has improvement than it, but not statistically significant.
(3) by above pharmacodynamic study results suggest, the effective initial dose of Danhong for injection clinical application is about 1.5～3mgkg
-1, recommend the clinical treatment congestion type pulmonary heart disease to intend being about 90～180mg with dosage in human body body weight 60kg.
4, Danhong for injection is to the influence of clotting time of mice
Purpose: observe Danhong for injection repeatedly the tail administration to the influence of clotting time of mice.
Method: 50 of healthy adult kunming mices are divided into blank group (Veh), the basic, normal, high dosage group of Danhong for injection and positive controls, 10 every group, male and female half and half at random by body weight.The tail administration is 3 days continuously, and the Veh group gives 0.9% sodium chloride injection of respective volume, and the Danhong for injection dosage is respectively 15mgkg
-1, 30mgkg
-1And 60mgkg
-1, positive controls gives DANHONG ZHUSHEYE, and dosage is 20mlkg
-1, after the last administration, plucked a branch hole ball rapidly with the curved tweezer of ophthalmology in 1 hour, give up the First Blood, on the microscope slide of cleaning, diameter is about 5～10mm with droplet of blood, manual time-keeping, provoke gently inwards 1 time with cleaning pin autoblood edge every 30s, observation has or not the blood streak to provoke.Be clotting time from the blood sampling beginning to provoking a time blood.
The result: compare with the Veh group, each dosage group clotting time of mice of Danhong for injection obviously prolongs, and wherein low dose group prolongs 27s, but not statistically significant.Middle dosage group prolongs 54s, has significant difference (P＜0.05).The high dose group clotting time of mice prolongs 129s, has remarkable significant difference (P＜0.01).Compare with positive controls, low dose group has significant difference (P＜0.05), and middle and high dosage group does not have remarkable significant difference, and concrete experimental data sees Table 15.
Table 15 Danhong for injection is to the influence of clotting time of mice
Annotate: n=10;
*P＜0.05
*Compare with the Veh group P＜0.01;
ΔCompare with the DANHONG ZHUSHEYE group P＜0.05.
Conclusion: (1) Danhong for injection 15mgkg
-1Can certain prolongation effect be arranged to clotting time of mice, but compare no difference of science of statistics with the Veh group.30mgkg
-1Can obviously prolong clotting time of mice, high dose group 60mgkg
-1Effect is more obvious.And with the increase of dosage, Danhong for injection increases progressively clotting time of mice, shows tangible dose-effect relationship.
(2) compare with the positive control drug DANHONG ZHUSHEYE, the low dose group curative effect does not have it obvious, and middle and high dosage group action effect has improvement than it, but not statistically significant.
(3) by above pharmacodynamic study results suggest, the effective initial dose of Danhong for injection clinical application is about 1.5～3mgkg
-1, recommend clinical treatment to intend being about 90～180mg with dosage in human body body weight 60kg.
5, Danhong for injection is to the influence of rat platelet aggregation rate
Purpose: observe Danhong for injection repeatedly the tail administration to the influence of rat platelet aggregation rate.
Method: get 50 of healthy adult Wistar rats, be divided into blank group (Veh), the basic, normal, high dosage group of Danhong for injection and positive controls at random by body weight.Every group 10, male and female half and half.The tail administration is 3 days continuously, and the Veh group gives 0.9% sodium chloride injection of respective volume, and the Danhong for injection dosage is respectively 10mgkg
-1, 20mgkg
-1And 40mgkg
-1, positive controls gives DANHONG ZHUSHEYE, and dosage is 12mlkg
-1, the 1h jugular sinus is got blood after the last administration, 3.8% sodium citrate anticoagulant.With anticoagulation centrifugal (800rpm, 10min), drawing upper plasma (is platelet rich plasma, PRP) with remainder recentrifuge (3000rpm, 15min), drawing upper plasma (is platelet poor plasma, PPP), survey the variation of light transmittance then with platelet aggregation instrument, ask the calculation platelet aggregation rate, concrete experimental data is shown in table 16.
Table 16 Danhong for injection is to the influence of the influence of rat platelet aggregation rate
Annotate:
*P＜0.05,
*Compare with the Veh group P＜0.01;
ΔP＜0.05,
The Δ ΔCompare with the DANHONG ZHUSHEYE group P＜0.01.
The result: compare with the Veh group, the basic, normal, high dosage group of Danhong for injection rat platelet aggregation rate all obviously descends, and wherein low dosage makes platelet aggregation rate descend 10%, but no difference of science of statistics.Middle and high dosage group descends 14%, 22%, and significant difference (P＜0.05) is all arranged, and high dose group difference extremely significantly (P＜0.01) illustrates that Danhong for injection can effectively suppress ADP and the inductive platelet aggregation rate of Collagen.Compare the basic, normal, high dosage group of Danhong for injection not statistically significant with positive controls.
Conclusion: (1) Danhong for injection 10mgkg
-1Can reduce the rat platelet aggregation rate to a certain extent.20mgkg
-1Remarkable anticoagulant, 40mgkg
-1Inhibitory action is stronger.Increase with dosage simultaneously, the anticoagulant effect strengthens, and certain dose-effect relationship is arranged.
(2) compare with the positive control drug DANHONG ZHUSHEYE, low, middle dosage group effect is not remarkable, and the high dose group curative effect has further improvement than it, but does not have significant difference.
(3) by above pharmacodynamic study results suggest, the effective initial dose of Danhong for injection clinical application is about 1.7～3.3mgkg
-1, recommend clinical treatment to intend being about 100～200mg with dosage in human body body weight 60kg.
Claims (3)
1. the preparation method of Danhong for injection, the preparation method that it is characterized in that Danhong for injection is carried out as follows: one, in Radix Salviae Miltiorrhizae and Flos Carthami medical material weight ratio is that 3: 1 ratio is got Radix Salviae Miltiorrhizae and Flos Carthami medical material, then according to the salvianolic acid B of following method extraction and the S-A Hydroxysafflor yellow A of following method extraction, it is 75%～99% that adding water for injection makes the water content that is mixed with the DANHONG medicinal liquid and makes the DANHONG medicinal liquid, stirring the pH value of regulating the DANHONG medicinal liquid with sodium hydroxide solution in the back is 4.0～4.5, under 0～10 ℃ condition, left standstill 12～48 hours, wherein the extracting method of salvianolic acid B carries out as follows: 1, add 8～18 times of salvia piece quality to the red rooted salvia decoction pieces earlier, mass concentration is that 35%～60% ethanol and volume are ethanol volume 1 ‰～4 ‰, concentration is the soak with hydrochloric acid 1～2 hour of 1mol/L, reflux, extract, is 1.5～3 hours then, leach danshen solution, add 6～16 times of medicinal residues quality to medicinal residues again, mass concentration is that 35%～60% ethanol and volume are ethanol volume 1 ‰～4 ‰, concentration is the hydrochloric acid of 1mol/L, reflux, extract, 1～2 hour, leach danshen solution, the danshen solution that merges extracted twice, to become relative density be 1.16～1.24 Radix Salviae Miltiorrhizae clear paste to concentrating under reduced pressure again; 2, the water that adds 3～5 times of Radix Salviae Miltiorrhizae clear paste weight in the Radix Salviae Miltiorrhizae clear paste, limit add the waterside and stir, and leave standstill under the room temperature 12～24 hours, refilter, and it is 2.8～3.2 that Radix Salviae Miltiorrhizae filtrate is regulated pH value with hydrochloric acid, obtains Radix Salviae Miltiorrhizae acidify filtrate; 3, with the macroporous adsorptive resins pH value be 2.8～3.2 hcl acidifying, the Radix Salviae Miltiorrhizae acidify filtrate that step 2 is obtained is splined on the macroporous absorption post, with 5～7 times of resin volume pH value is 2.8～3.2 hydrochloric acid flushing impurity, the reuse mass concentration is 35%～55% ethanol elution, collect the Radix Salviae Miltiorrhizae eluent of 1.5～2.5 times of resin volumes, the pH value of regulating the Radix Salviae Miltiorrhizae eluent with sodium hydroxide solution is 4.0～4.2, is evaporated to relative density and is 1.08～1.25 salvianolic acid clear paste; Promptly obtain salvianolic acid B; The extracting method of S-A Hydroxysafflor yellow A carries out as follows: 1, earlier add the water logging bubble 20～40 minutes that quality is 16～20 times of Flos Carthami quality to Flos Carthami, decocted 20～40 minutes, leach the Flos Carthami medicinal liquid, adding quality to medicinal residues again is the water of 14～18 times of medicinal residues quality, decocted 20～40 minutes, leach the Flos Carthami medicinal liquid, merge the Flos Carthami medicinal liquid that leaches for twice, be cooled to room temperature; 2, the Flos Carthami medicinal liquid is regulated pH value to 1.9～2.2 with hydrochloric acid, leaves standstill 6～24 hours, refilters, and obtains Flos Carthami acidify filtrate; 3, with the macroporous adsorptive resins pH value be 1.9～2.2 hcl acidifying, the Flos Carthami acidify filtrate that step 2 is obtained is splined on the macroporous absorption post, with 6～8 times of resin volume pH value is 1.9～2.2 hydrochloric acid flushing impurity, the reuse mass concentration is 8%～15% ethanol elution, collect the Flos Carthami eluent of 4.5～6.0 times of resin volumes, the pH value of regulating the Flos Carthami eluent with sodium hydroxide solution is 4.0～4.2, is evaporated to relative density and is 1.08～1.25 Hydroxy Carthamus yellow clear paste; Promptly get S-A Hydroxysafflor yellow A; Two, earlier behind the filtering with microporous membrane with 0.22 μ m or 0.45 μ m, the Millipore ultrafiltration post that passes through the molecular weight that dams again and be 30K or 50K carries out ultrafiltration, with packing of DANHONG filtrate and lyophilizing; Promptly obtain Danhong for injection.
2. the preparation method of Danhong for injection according to claim 1 is characterized in that making the water content of DANHONG medicinal liquid in the step 1 is 88%.
3. the preparation method of Danhong for injection according to claim 1 is characterized in that the pH value with sodium hydroxide solution adjusting DANHONG medicinal liquid is 4.3 in the step 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102365632A CN101879155B (en) | 2007-12-04 | 2007-12-04 | Method for preparing dan hong for injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102365632A CN101879155B (en) | 2007-12-04 | 2007-12-04 | Method for preparing dan hong for injection |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710144744 Division CN101168539B (en) | 2007-12-04 | 2007-12-04 | Method for extracting salvianolic acid B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101879155A CN101879155A (en) | 2010-11-10 |
| CN101879155B true CN101879155B (en) | 2011-12-21 |
Family
ID=43051387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102365632A Active CN101879155B (en) | 2007-12-04 | 2007-12-04 | Method for preparing dan hong for injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101879155B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102357118A (en) * | 2011-11-03 | 2012-02-22 | 哈药集团中药二厂 | Extraction method of salvia extract and safflower extract and preparation method of salvia-safflower oral preparation |
| CN103980239B (en) * | 2013-02-07 | 2016-04-13 | 浙江永宁药业股份有限公司 | Hydroxyl radical carthamin yellow carthamus A sodium and production method thereof and purposes |
| CN104997767A (en) * | 2014-04-25 | 2015-10-28 | 西安世纪盛康药业有限公司 | Pharmaceutical composition containing salvianolic acid B and pharmaceutical application thereof |
-
2007
- 2007-12-04 CN CN2010102365632A patent/CN101879155B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101879155A (en) | 2010-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101168539B (en) | Method for extracting salvianolic acid B | |
| CN104208302A (en) | Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof | |
| CN101524469B (en) | Chinese herbal medicine compound preparation for treating congestive heart failure and preparation method thereof | |
| CN102028700A (en) | Medicinal composition and preparation method thereof | |
| CN101879155B (en) | Method for preparing dan hong for injection | |
| CN103520193A (en) | Pharmaceutical composition and preparation method thereof | |
| CN101891723B (en) | Method for extracting hydroxysafflor yellow A | |
| CN101940605B (en) | Chinese loropetalum leaf total flavonol extract and medical application thereof | |
| CN101822729B (en) | Medicine for treating slow arrhythmia sick sinus syndromes | |
| CN104623262B (en) | A kind of Shenmai injection and preparation method thereof | |
| CN103405501B (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN102078509B (en) | Traditional Chinese medicine preparation for treating ophthalmorrhagia and preparation method thereof | |
| CN102526147A (en) | Method for purifying panax notoginseng total saponins and preparation of panax notoginseng total saponins | |
| CN100431562C (en) | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN101711793B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| WO2022135329A1 (en) | Pharmaceutical composition containing erigerontis herba, ginseng radix et rhizoma, ophiopogonis radix and schisandrae chinensis fructus | |
| CN105999195A (en) | Preparation method of radix codonopsis, ramulus cinnamomi and poria cocos preparation | |
| CN101700264B (en) | Application of pseudo-ginseng and extract thereof in preparing medicament for curing and/or preventing diabetic neuropathies | |
| CN104257755A (en) | Composition with effect of treating diabetes as well as preparation method and application of composition | |
| CN104906294A (en) | Traditional Chinese medicine combination for treating senile dementia and detection method thereof | |
| CN105535890B (en) | A kind of pharmaceutical composition and preparation method thereof for treating cardiovascular disease | |
| CN104984268A (en) | Traditional Chinese medicine composition treating cerebral thrombosis and preparing method of traditional Chinese medicine composition | |
| CN100400074C (en) | Chinese medicinal preparation for freating coronary heart disease, brain arteriosclerosis and its preparation method | |
| CN102357118A (en) | Extraction method of salvia extract and safflower extract and preparation method of salvia-safflower oral preparation | |
| CN103238834A (en) | Composition for treating cutaneous pruritus and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220127 Address after: 150000 room a307-169, building 20, innovation and entrepreneurship Plaza, science and technology innovation city, high tech Industrial Development Zone, Harbin, Heilongjiang Province (178 Xiuyue Street) Patentee after: Harbin Pharmaceutical Group traditional Chinese Medicine Co.,Ltd. Address before: 150078 No. 243 Airport Road, Daoli District, Heilongjiang, Harbin Patentee before: The Second Chinese Medicine Factory, Harbin Pharmaceutical Group Co.,Ltd. |
|
| TR01 | Transfer of patent right |